Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV 1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing –